@article{f74a409081af4bcfa72770a81a0f6400,
title = "Exenatide modulates visual cortex responses",
abstract = "Background: Increasing evidence suggests that metabolism affects brain physiology. Here, we examine the effect of GLP-1 on simple visual-evoked functional Magnetic Resonance Imaging (fMRI) responses in cortical areas. Methods: Lean (n = 10) and nondiabetic obese (n = 10) subjects received exenatide (a GLP-1 agonist) or saline infusion, and fMRI responses to visual stimuli (food and nonfood images) were recorded. We analysed the effect of exenatide on fMRI signals across the cortical surface with special reference to the visual areas. We evaluated the effects of exenatide on the raw fMRI signal and on the fMRI signal change during visual stimulation (vs rest). Results: In line with previous studies, we find that exenatide eliminates the preference for food (over nonfood) images present under saline infusion in high-level visual cortex (temporal pole). In addition, we find that exenatide (vs saline) also modulates the response of early visual areas, enhancing responses to both food and nonfood images in several extrastriate occipital areas, similarly in obese and lean participants. Unexpectedly, exenatide increased fMRI raw signals (signal intensity during rest periods without stimulation) in a large occipital region, which were negatively correlated to BMI. Conclusions: In both lean and obese individuals, exenatide affects neural processing in visual cortex, both in early visual areas and in higher order areas. This effect may contribute to the known effect of GLP1 analogues on food-related behaviour.",
keywords = "exenatide, fMRI, obesity, visual cortex",
author = "Paola Binda and Roy Eldor and Claudia Huerta and John Adams and John Lancaster and Peter Fox and {Del Prato}, Stefano and Ralph DeFronzo and Muhammad Abdul-Ghani and Giuseppe Daniele",
note = "Funding Information: European Research Council (ERC), Grant/ Award Number: 801715 ‐ PUPILTRAITS; National Institutes of Health, Grant/Award Number: ROI DK097554‐01; Qatar Foundation, Grant/Award Number: NPRP 4‐248‐3‐ 076 Funding Information: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 801715 - PUPILTRAITS). This study was partly supported by Qatar Foundation grant NPRP 4-248-3-076 and National Institutes of Health grant ROI DK097554-01 to M.A.-G. Support of P.B. additionally came from the European Research Council, under the grant Ecsplain. Exenatide was provided by AstraZeneca. The authors thank Sandra Martinez, RN, for her excellent care of the patients during the study and Lorrie Albarado and Shannon Balmer, from the University of Texas Health Science Center, for their expert secretarial assistance in preparation of the manuscript. Funding Information: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 801715 ‐ PUPILTRAITS). This study was partly supported by Qatar Foundation grant NPRP 4‐ 248‐3‐076 and National Institutes of Health grant ROI DK097554‐ 01 to M.A.‐G. Support of P.B. additionally came from the European Research Council, under the grant Ecsplain. Exenatide was provided by AstraZeneca. Publisher Copyright: {\textcopyright} 2019 John Wiley & Sons, Ltd.",
year = "2019",
month = sep,
day = "1",
doi = "10.1002/dmrr.3167",
language = "English (US)",
volume = "35",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "6",
}